NASDAQ$VTGN
Vistagen Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of fiscal year 2023 and provided a corporate update.
VistaGen Therapeutics reported its financial results for the first quarter of fiscal year 2023 ended June 30, 2022. The company is evaluating the results of PALISADE-1 and conducting an interim analysis of PALISADE-2. They anticipate a considerable reduction in external spending to conserve cash.
- PH94B did not achieve its primary efficacy endpoint during PALISADE-1.
- Enrollment in PALISADE-2 has been paused while an interim analysis of available data is conducted.
- Preliminary data from the PALISADE open label safety study suggest cumulative functional improvement with PH94B use.
- The company anticipates submission of its PH10 IND in MDD in 2022 and initiation of a small U.S. Phase 1 study in 2022 to facilitate potential Phase 2B development of PH10 as a rapid-onset, stand-alone treatment of MDD in 2023.
Headline financials
Revenue & EPS history
Vistagen · Revenue · Quarterly
$310K
Revenue by segment
Vistagen · $1.27M total across 1 segment · Q4 2026
- Sublicense and other revenue$1.27M—100.0%
Forward guidance
VistaGen anticipates a considerable reduction in external spending to conserve cash and extend the Company’s cash runway covering at least the next 12 months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+2.5%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
39%
23 / 59 earnings
Positive
+94.1%
Q4 2012
Best reaction
-24.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +19.2% | +17.1% | — | |
| Q3 2026 | -3.5% | -7.0% | +7.0% | |
| Q2 2026 | +0.0% | +18.4% | +11.8% | |
| Q1 2026 | +8.1% | +7.3% | +30.0% | |
| Q4 2025 | +7.0% | +5.7% | -3.9% | |
| Q3 2025 | +4.2% | +0.0% | -5.3% | |
| Q2 2025 | +1.3% | -5.5% | -16.1% | |
| Q1 2025 | -2.7% | -2.7% | -5.3% | |
| Q4 2024 | +0.3% | -4.3% | +6.3% | |
| Q3 2024 | +4.7% | -1.0% | -23.9% | |
| Q2 2024 | -16.6% | +3.2% | +51.0% | |
| Q1 2024 | -8.8% | -10.8% | -4.3% | |
| Q4 2023 | +6.5% | +19.5% | +7.1% | |
| Q3 2023 | -24.0% | -28.0% | -44.0% | |
| Q2 2023 | +45.5% | +45.5% | +9.1% | |
| Q1 2023 | -5.9% | -5.9% | +23.5% | |
| Q4 2022 | -3.9% | -10.8% | -85.3% | |
| Q3 2022 | -7.4% | -1.2% | -26.5% | |
| Q2 2022 | +0.4% | -7.7% | -21.0% | |
| Q1 2022 | +2.2% | +0.0% | +11.4% | |
| Q4 2021 | +10.9% | +19.4% | -5.6% | |
| Q3 2021 | -5.0% | -1.0% | +16.9% | |
| Q2 2021 | +2.9% | +5.9% | +8.8% | |
| Q1 2021 | -7.3% | -14.6% | -25.6% | |
| Q4 2020 | +1.9% | +1.9% | +76.9% | |
| Q3 2020 | -12.2% | -10.8% | -45.9% | |
| Q2 2020 | +0.9% | +0.0% | -58.9% | |
| Q1 2020 | -12.7% | -7.3% | +100.0% | |
| Q4 2019 | -5.3% | -2.7% | -30.7% | |
| Q3 2019 | -2.9% | -16.1% | -26.4% | |
| Q2 2019 | -3.3% | -0.9% | -19.3% | |
| Q1 2019 | -3.1% | +2.3% | +8.6% | |
| Q4 2018 | +1.5% | +3.0% | -2.3% | |
| Q3 2018 | +3.4% | +8.6% | +9.5% | |
| Q2 2018 | -1.3% | -3.7% | +125.0% | |
| Q1 2018 | +0.0% | +5.2% | -6.4% | |
| Q4 2017 | +2.2% | -3.3% | +11.5% | |
| Q3 2017 | -10.2% | -19.3% | -28.8% | |
| Q2 2017 | +2.4% | -1.1% | -6.1% | |
| Q1 2017 | +6.3% | +7.8% | +28.5% | |
| Q4 2016 | -9.9% | -4.2% | -8.8% | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | +0.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | -8.6% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +94.1% | — | — | |
| Q4 2012 | +94.1% | — | — | |
| Q3 2012 | +1.8% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q1 2010 | — | — | — | |
| Q4 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro